

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
CSLL-D 1 of 6 Internal request In response to the FDA approval of ibrutinib + obinutuzumab as an option for treatment naïve patients with CLL/SLL based on the data from iLLUMINATE study, the panel voted on the addition of this regimen for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients ≥65 y and younger patients with significant comorbidities.	In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + obinutuzumab, the panel consensus was to include ibrutinib + obinutuzumab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for frail patients with significant comorbidity and patients age ≥65 y and younger patients with significant comorbidities with a category 2B recommendation, other recommended regimen. <ul style="list-style-type: none"> Moreno C, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:43-56. 	15	5	1	6
External request Submission request from Pharmacyclics LLC and Janssen Biotech, Inc. for first-line therapy for CLL/SLL without del(17p)/TP53 mutation for <65 y without significant comorbidities: Ibrutinib + rituximab: Recommend as Category 1, preferred regimen, for patients with unmutated and mutated <i>IGHV</i> .	In the absence of data from randomized clinical trial that has compared ibrutinib vs ibrutinib + rituximab, the panel consensus was to include ibrutinib + rituximab as a first-line therapy for CLL/SLL without del(17p)/TP53 mutation for patients <65 y without significant comorbidities with a category 2B recommendation, other recommended regimen. <ul style="list-style-type: none"> Shanafelt T, Wand V, Kay N, et al. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912) [abstract]. Blood 2018; 132: Abstract LBA-4. 	12	8	1	6